ADENOSINE A3 RECEPTORS: A NEW THERAPEUTIC APPROACH IN CANCER.

被引：2

作者：

Gaspar, Alexandra ^{[1
]}

Silva, Tiago ^{[1
]}

Borges, Fernanda ^{[1
]}

机构：

[1] Univ Porto, Fac Ciencias, Dept Quim & Bioquim, P-4000 Oporto, Portugal

来源：

QUIMICA NOVA | 2011年 / 34卷 / 08期

关键词：

cancer; AR A(3); ligands; HIGHLY POTENT; SPECIES-DIFFERENCES; PHARMACOLOGICAL EVALUATION; SELECTIVE ANTAGONISTS; PURINE DERIVATIVES; MELANOMA-CELLS; LIGANDS; AGONISTS; SERIES; AFFINITY;

D O I：

10.1590/S0100-40422011000800022

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

ADENOSINE A(3) RECEPTORS: A NEW THERAPEUTIC APPROACH IN CANCER. Cancer is a multi-factorial disease linked with different initiating causes, cofactors and promoters, and several types of cellular damage. Advancing knowledge on the cellular and molecular biology of the processes that regulate cell proliferation, cell differentiation and cellular responses to external signals, has provided a wealth of information about the cancer cell and how it differs from a normal one. These findings make available a number of potential targets for new therapeutic approaches. The Medicinal Chemistry artwork performed so far in the development of selective and potent adenosine receptor A(3) ligands, a current cancer target, will be highlighted in this work.

引用

页码：1417 / 1424

页数：8

共 50 条

[1] A3 adenosine receptors
Jacobson, KA
Tchilibon, S
Joshi, BV
Gao, ZG
ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 38, 2003, 38 : 121 - 130
[2] New high affinity agonists at A3 adenosine receptors
Klotz, KN
Volpini, R
Vittori, S
Cristalli, G
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 357 (04) : R32 - R32
[3] A new role for adenosine A3 receptors in chronic neuroinflammation
van der Putten, Celine
Ella, Zuiderwijk-Sick A.
van Straalen, Linda
Eveline, de Geus D.
Leonie, Boven A.
Ivanela, Kondova
Ad, Ijzerman P.
Jeffrey, Bajramovic J.
JOURNAL OF NEUROIMMUNOLOGY, 2010, 228 (1-2) : 163 - 163
[4] A NEW ROLE FOR ADENOSINE A3 RECEPTORS IN CHRONIC NEUROINFLAMMATION
Bajramovic, J. J.
van der Putten, C.
Zuiderwijk-Sick, E. A.
van Straalen, L.
de Geus, E. D.
Boven, L. A.
Kondova, I
Ijzerman, A. P.
GLIA, 2011, 59 : S151 - S152
[5] Targeting the A3 adenosine receptor (A3AR):: A new approach for cancer treatment
Fishman, P
Bar-Yehuda, S
Madi, L
DRUG DEVELOPMENT RESEARCH, 2002, 56 (04) : 547 - 547
[6] A3 and A2a adenosine receptors as targets in cancer therapeutics
Tote, S.
Ghosh, R.
Kulkarni, J. S.
Kadam, V. J.
INDIAN JOURNAL OF PHARMACOLOGY, 2008, 40 : 197 - 197
[7] Adenosine A3 receptors and cytokine production
不详
EXPERT OPINION ON THERAPEUTIC PATENTS, 1998, 8 (08) : 1049 - 1051
[8] Adenosine A3 receptors and viability of astrocytes
Abbracchio, MP
Ceruti, S
Brambilla, R
Barbieri, D
Camurri, A
Franceschi, C
Giammarioli, AM
Jacobson, KA
Cattabeni, F
Malorni, W
DRUG DEVELOPMENT RESEARCH, 1998, 45 (3-4) : 379 - 386
[9] Partial agonists for A3 adenosine receptors
Gao, ZG
Jacobson, KA
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2004, 4 (08) : 855 - 862
[10] Are A3 adenosine receptors expressed in the brain?
Rivkees, SA
Thevananther, S
Hao, HP
NEUROREPORT, 2000, 11 (05) : 1025 - 1030

← 1 2 3 4 5 →